• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青蒿素与奎宁对恶性疟原虫的体外重复给药:体内药代动力学模拟

Repetitive dosing of artemisinin and quinine against Plasmodium falciparum in vitro: a simulation of the in vivo pharmacokinetics.

作者信息

Bwijo B, Hassan Alin M, Abbas N, Eriksson O, Björkman A

机构信息

Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institutet, Huddinge University Hospital, Sweden.

出版信息

Acta Trop. 1997 Apr 30;65(1):11-22. doi: 10.1016/s0001-706x(96)00565-7.

DOI:10.1016/s0001-706x(96)00565-7
PMID:9140510
Abstract

Plasmodium falciparum (F32) parasites were exposed to artemisinin and quinine for 3 and 4 h, respectively, once or twice daily and for 3, 5 or 7 days. Between the peaks the parasites were exposed to trough concentrations. Continuous drug exposure was also assessed for comparison. After drug exposure, the cultures were extended for an observation period of up to 30 days to assess the viability of the parasites remaining after drug exposure. For artemisinin, a critical threshold concentration of 3 x 10(-8) M was required for growth inhibition. Dosing twice daily for at least 5 days was also critical. Prolonging the duration of drug exposure to 7 days further increased the efficacy. For quinine the results were quite different. The concentration dependency of the efficacy was more gradual. On the other hand dosing once daily appeared to be nearly as effective as twice daily and radical clearance was obtained even after 3 days of exposure at peak concentrations of 10(-5) M. A concentration of 10(-6) M provided the same effect if the duration was extended to 7 days. There was a strong similarity between estimated concentrations of free unbound drug required for radical clearance in vitro and those empirically required for clinical efficacy in vivo. This suggests that the in vitro model represents an appropriate model for estimating drug efficacy and pharmacodynamics if the in vitro system is adapted to simulate in vivo pharmacokinetics.

摘要

恶性疟原虫(F32)寄生虫分别暴露于青蒿素和奎宁中3小时和4小时,每天给药一次或两次,持续3天、5天或7天。在药物浓度峰值之间,寄生虫暴露于谷浓度。还评估了持续药物暴露以作比较。药物暴露后,将培养物延长长达30天的观察期,以评估药物暴露后剩余寄生虫的活力。对于青蒿素,生长抑制所需的临界阈值浓度为3×10⁻⁸ M。每天给药两次至少5天也很关键。将药物暴露时间延长至7天可进一步提高疗效。对于奎宁,结果则大不相同。疗效的浓度依赖性更为渐进。另一方面,每天给药一次似乎与每天给药两次几乎同样有效,即使在峰值浓度为10⁻⁵ M的情况下暴露3天后也能实现根治性清除。如果将暴露时间延长至7天,10⁻⁶ M的浓度也能产生相同的效果。体外根治性清除所需的游离未结合药物估计浓度与体内临床疗效所需的经验浓度之间存在很强的相似性。这表明,如果体外系统经过调整以模拟体内药代动力学,那么体外模型是评估药物疗效和药效学的合适模型。

相似文献

1
Repetitive dosing of artemisinin and quinine against Plasmodium falciparum in vitro: a simulation of the in vivo pharmacokinetics.青蒿素与奎宁对恶性疟原虫的体外重复给药:体内药代动力学模拟
Acta Trop. 1997 Apr 30;65(1):11-22. doi: 10.1016/s0001-706x(96)00565-7.
2
Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics.
Trop Med Int Health. 1997 May;2(5):461-7.
3
Concentration and time dependency of artemisinin efficacy against Plasmodium falciparum in vitro.
Am J Trop Med Hyg. 1994 Jun;50(6):771-6. doi: 10.4269/ajtmh.1994.50.771.
4
In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum.青蒿素与阿托伐醌、奎宁和甲氟喹对恶性疟原虫的体外相互作用。
Antimicrob Agents Chemother. 2002 May;46(5):1510-5. doi: 10.1128/AAC.46.5.1510-1515.2002.
5
In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs.恶性疟原虫对奎宁和青蒿素类药物的体外阶段特异性敏感性。
Int J Parasitol. 1996 May;26(5):519-25. doi: 10.1016/0020-7519(96)89380-5.
6
In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance.用于评估临床相关抗疟交叉耐药性的体内-体外模型
Am J Trop Med Hyg. 2001 Dec;65(6):696-9. doi: 10.4269/ajtmh.2001.65.696.
7
In vitro susceptibility of Plasmodium falciparum isolates in Vietnam to artemisinin derivatives and other antimalarials.越南恶性疟原虫分离株对青蒿素衍生物及其他抗疟药的体外敏感性
Acta Trop. 1997 Feb;63(2-3):151-8. doi: 10.1016/s0001-706x(96)00618-3.
8
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum.抗疟药物可降低恶性疟原虫的细胞黏附和红细胞凝聚。
J Infect Dis. 1996 Mar;173(3):691-8. doi: 10.1093/infdis/173.3.691.
9
In vitro susceptibility of Plasmodium falciparum to quinine: relation to parasite density and drug distribution in culture fractions.
Trop Med Int Health. 1996 Dec;1(6):802-9. doi: 10.1111/j.1365-3156.1996.tb00114.x.
10
In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives.柬埔寨恶性疟原虫分离株对卤泛群、咯萘啶和青蒿素衍生物的体外敏感性
Ann Trop Med Parasitol. 1994 Apr;88(2):137-44. doi: 10.1080/00034983.1994.11812851.

引用本文的文献

1
Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.改变抗疟药物治疗方案可能会显著提高并恢复药物疗效。
Antimicrob Agents Chemother. 2015 Oct;59(10):6419-27. doi: 10.1128/AAC.00482-15. Epub 2015 Aug 3.
2
Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy?恶性疟原虫对青蒿素的抗性:与休眠相关的过程?
Int J Parasitol Drugs Drug Resist. 2012 Dec 1;2:249-255. doi: 10.1016/j.ijpddr.2012.01.001. Epub 2012 Jan 27.
3
Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure.
青蒿素诱导恶性疟原虫休眠:持续时间、恢复率及其对治疗失败的影响
J Infect Dis. 2010 Nov 1;202(9):1362-8. doi: 10.1086/656476.